Vir Biotechnology, Inc. Stock price

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
11.24 USD 0.00% Intraday chart for Vir Biotechnology, Inc. -2.52% +11.73%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 43.7M Sales 2025 * 45M Capitalization 1.52B
Net income 2024 * -573M Net income 2025 * -600M EV / Sales 2024 * 7.17 x
Net cash position 2024 * 1.2B Net cash position 2025 * 681M EV / Sales 2025 * 18.6 x
P/E ratio 2024 *
-2.66 x
P/E ratio 2025 *
-2.8 x
Employees 587
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.39%
More Fundamentals * Assessed data
Dynamic Chart
1 week-2.52%
1 month+23.25%
3 months+16.00%
6 months-10.15%
Current year+11.73%
More quotes
1 week
11.14
Extreme 11.14
12.00
1 month
8.42
Extreme 8.415
12.00
Current year
8.42
Extreme 8.415
12.00
1 year
7.72
Extreme 7.72
27.48
3 years
7.72
Extreme 7.72
68.20
5 years
7.72
Extreme 7.72
141.01
10 years
7.72
Extreme 7.72
141.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 -
Director of Finance/CFO 53 23-03-26
Chief Tech/Sci/R&D Officer - Nov. 05
Members of the board TitleAgeSince
Director/Board Member 72 20-07-01
Director/Board Member 59 16-12-31
Director/Board Member 56 16-08-31
More insiders
Date Price Change Volume
24-03-01 11.24 0.00% 1,313,585
24-02-29 11.24 -3.10% 1,215,959
24-02-28 11.6 +1.49% 1,524,069
24-02-27 11.43 -3.95% 2,275,828
24-02-26 11.9 +3.21% 1,505,833

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline consists of product candidates targeting hepatitis B virus (HBV), hepatitis delta virus (HDV) and human immunodeficiency virus (HIV). The Company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). Its pipeline includes VIR-2218, VIR-3434, VIR-1388, VIR-7229, VIR-2482, VIR-2981, VIR-8190, and VIR-1949. VIR-2218 is an investigational HBV-targeting siRNA. VIR-1388 is an investigational HIV T cell vaccine based on human cytomegalovirus (HCMV).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
11.24 USD
Average target price
29.5 USD
Spread / Average Target
+162.46%
Consensus
  1. Stock
  2. Equities
  3. Stock Vir Biotechnology, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW